Leifeng Liang

7PUBLICATIONS
3CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Gene and molecular therapyPredictive and prognostic markersOral and maxillofacial surgery
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Jul 03, 2026
DHRS2 as a Novel Thalidomide Target Regulating Mitophagy and Inflammation in Head and Neck Squamous Cell Carcinoma.

|May 15, 2026
Combination Therapy With AOPT Intense Pulsed Light (Dual-Band Vascular Filter) and 1064 nm Nd:YAG Laser for Solitary, Superficial Infantile Hemangioma: A Retrospective Study.

|Feb 12, 2026
Integrated single-cell and transcriptomic analysis of CD8<sup>+</sup>CD101<sup>+</sup>TIM3<sup>+</sup> T cells in hepatocellular carcinoma: implications for tumor microenvironment and prognostic modeling.

Feifeng Ran, Zhang Jiang, Lilin Que

|Jul 15, 2025
Construction and validation of a machine learning model to predict the risk of nasopharyngeal carcinoma using multimodal clinical data: a single-center, retrospective study.

Xiao Li, Zuheng Wang, Wenting Chen

|Jun 18, 2025
Identification of metabolism-associated molecular classification for effect and prognosis in lung adenocarcinoma based on multidatabases including the cancer genome atlas and gene expression omnibus.

Lilin Que, Zhibing Liu, Yinghui Wu

|Sep 28, 2024
Thalidomide attenuates radiation-induced apoptosis and pro-inflammatory cytokine secretion in oral epithelial cells by promoting LZTS3 expression.

Leifeng Liang, Mei Gan, Huanshuo Miao

Pageof 2

Frequent Collaborators

1 joint publications

Feifeng Ran

1 joint publications

Rensheng Wang

1 joint publications

Changyuan Wei